Navigation Links
AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies
Date:4/20/2009

-- Key Data are New Releases for the Company Building on Milestones with Recent FDA Meetings and Technology Discoveries --

DENVER, April 20 /PRNewswire-FirstCall/ -- DXL625 monoclonal antibodies appear to be superior to commercial-stage antibodies in their ability to attach and deplete NHL in late stage pre-clinical studies, according to research conducted at InNexus Biotechnology Inc. (Toronto Stock Exchange: IXS.V, http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology. The potency was achieved with comparable safety even at levels one hundred times that required for therapeutic efficacy, according to several studies presented at the American Association of Cancer Research (AACR) 100th Annual Meeting this past weekend. DXL625 is designed to bind CD20, a protein receptor expressed on normal B cells and over-expressed on cancerous B cells.

InNexus has previously announced that the United States Food and Drug Administration had completed its comprehensive review of the development plans for DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL). InNexus' submission included detailed information on plans for a Phase I clinical program, preclinical pharmacology and toxicology data and its current manufacturing plans. The FDA noted at the time that the plans were suitable for the manufacture of Phase I product of DXL625 onsite at InNexus.

"The studies are an important validation of our core drug discovery platform and confirm our ability to significantly advance the state of the art in developing potentially superior biologics for major medical and commercial opportunities," said Jeff Morhet, Chairman and CEO at InNexus.

InNexus and institutional researchers author
'/>"/>

SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Fralex reaches 100th patient milestone in fibromyalgia study
2. WolfPAC(sm) Integrated Risk Management Announces 100th Sale
3. eRT Completes Milestone 100th Thorough QT Study
4. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
5. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
6. Sinovac Announces Postponement of Annual General Meeting
7. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
8. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
9. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
10. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
11. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 PAREXEL ... global clinical research organization , announced ... definitive agreement to acquire all of the ... a leading provider of specialized pharmacovigilance services, ... the collection, detection, assessment, monitoring, and prevention ...
(Date:3/25/2015)... of the most attractive in the emerging European region, ... economy and increasing government investment in healthcare, according to ... is set to grow at twice the pace of ... annually reaching an approximate market value of $43-60 billion ... Green Cross provides total healthcare solutions that address the ...
(Date:3/25/2015)... 25, 2015  S&P Capital IQ (MHFI) announced ... Report coverage on Abattis Bioceuticals Corp . ... is a specialty biotechnology company with capabilities through ... marketing proprietary ingredients, bio-similar compounds, patented equipment and ... North America . The company seeks to ...
(Date:3/25/2015)... SPRINGS, Fla. , March 25, 2015 /PRNewswire/ ... strategy and management consulting firm, has launched the ... publication to simplify tracking of ePrescribing regulatory requirements ... "The ePrescribing regulatory landscape continues to change ... to deliver what the industry, and ultimately patients, ...
Breaking Biology Technology:PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Point-of-Care Partners Launches the ePrescribing State Law Capsule 2
... March 23, 2011 Tengion, Inc. (Nasdaq: ... the addition of two renal research and clinical experts, ... from the Harvard Stem Cell Institute and ... & Development Advisors. This panel provides counsel to Tengion ...
... nanotubes dipped in a polymer solution equal the energy output ... of Case Western Reserve University engineers has found. The ... power output and maintain the other advantages by matching the ... they,ve proved the simple technique can knock down one of ...
... Spherix Incorporated (Nasdaq: SPEX), ... diabetes, metabolic syndrome and atherosclerosis; and providers of ... biotechnology and pharmaceutical companies, today announced that its ... the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference to be ...
Cached Biology Technology:Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel 2Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel 3Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel 4Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel 5Cheap catalyst made easy 2Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference 2Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference 3
(Date:3/23/2015)... NEW YORK , March 23, 2015   ... digital property management company, today announced that the Company ... platform for both enterprise and consumers at Connect:ID on ... D.C. HOYOS Labs will highlight the IEEE ... 1U TM ; and enterprise access control system. ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and Markets ... addition of the "India Sensors Market Forecast ... The sensor market is projected to ... Consumer electronics, automotive, industrial and healthcare ... in the country. In addition, adoption of MEMS ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report to ... for Iris Biometrics in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Latin America . ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... biomedical and health informatics, sent comments to the federal ... (DHHS/ ONCHIT), which has actively supported and incentivized the ... over the last year, and which solicited comment, through ... support for achieving meaningful use of EHRs in 2013 ...
... A new non-surgical post-mortem technique that has the ... the world has been pioneered by forensic pathologists and ... the University Hospitals of Leicester NHS Trust. The ... Forensic Pathology Unit, at the University of Leicester, has ...
... how farmers could protect themselves by growing a greater ... BioScience , has highlighted economical steps that farmers ... global climate change, including a greater frequency of extreme ... a policy priority for agriculture. The survey, by Brenda ...
Cached Biology News:AMIA on meaningful use: Invest in people and technology 2New non-surgical autopsy technique set to revolutionize post-mortem practice 2
... Concentrated x 10 This pH 9.9 ... prior to immunohistochemical staining procedures. It is ... mounted on glass slides. For particular antigens, ... especially effective. It should be noted that ...
... 9 (x 10) This product is ... heat-induced target retrieval prior to immunohistochemical staining ... formalin-fixed, paraffin-embedded tissue sections mounted on glass ... pH 6, the use of Target Retrieval ...
... Maximizer kit, 110 to 220 V, ... and doubles flow rates and valve ... The kit includes the Maximizer base ... kit, tubing kit, system cable 30, ...
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
Biology Products: